A first-in-class KIF11 degrader antibody conjugate (DAC) as a potential therapy targeting a broad spectrum of cancers. Role of Lu177 FAPI-09 therapy in combination with chemotherapy or immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback